AstraZeneca Files the Litigation Against Salubris About Ticagrelor Tablets
2018/01/19
On Jan 16, 2018, AstraZeneca officially filed a litigation to Beijing IP Court against the patent invalid announcement decision (No. 33591) of Ticagrelor Tablets made by Patent Reexamination Board of SIPO and asked it to revoke the invalid decision. On July 2011, Ticagrelor Tablets was approved to list through US the Food and Drug Administration (FDA). The important compound invention patent (No. 99815926.3) of Ticagrelor Tablets will be expired on Dec 2, 2019 and then many generic drug teams appear successively. As the most one of standing out in generic drug teams, Shenzhen Salubris Pharmaceutical Co., Ltd. (Salubris) firstly launched patent battle on Apr 27, 2017, appealing Patent Reexamination Board of SIPO to judge the compound invention patent (No. 99815926.3) of Ticagrelor Tablets is invalid. On Oct 17, 2017, issued by Patent Reexamination Board, the patent invalid examination decision (No. 33591) announced that the patent is invalid because of no equipment with creativeness. While AstraZeneca refused this decision and brought another administrative proceeding. At the sensitive period of China pharmaceutical patent linkage system reform, the patent dispute between AstraZeneca and Salubris is certainly concerned by the public and China IP will also further continue to follow up the case.
